Cargando…

Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran

AIM: We aimed to study the expression of CD24 and CD133 in colorectal cancer and normal adjacent tissues to assess a relationship between these markers and clinic-pathological characteristics and patient’s survival. BACKGROUND: Cancer stem cells are a group of tumor cells that have regeneration and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nosrati, Anahita, Naghshvar, Farshad, Maleki, Iradj, Salehi, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833852/
https://www.ncbi.nlm.nih.gov/pubmed/27099673
_version_ 1782427394762604544
author Nosrati, Anahita
Naghshvar, Farshad
Maleki, Iradj
Salehi, Fatemeh
author_facet Nosrati, Anahita
Naghshvar, Farshad
Maleki, Iradj
Salehi, Fatemeh
author_sort Nosrati, Anahita
collection PubMed
description AIM: We aimed to study the expression of CD24 and CD133 in colorectal cancer and normal adjacent tissues to assess a relationship between these markers and clinic-pathological characteristics and patient’s survival. BACKGROUND: Cancer stem cells are a group of tumor cells that have regeneration and multi-order differentiation capabilities. PATIENTS AND METHODS: Expression of CD24 and CD133 was studied in a paraffin block of colorectal cancer and normal tissues near tumors with the immuneohistochemical method in patients who were referred to Imam Khomeini Hospital in Sari. RESULTS: A total of 50 samples (25 males and 25 females) with a mean age of 67.57±13.9 years old with range 28-93 years, included 3 mucinous carcinoma and 47 adenocarcinoma. Expression of CD133 marker was negative in 29 cases and positive in 21 cases. Expression of CD24 in tissue near tumor cells was found in 30% of available samples. The relationship between expressing CD24 with treatment (surgery and chemotherapy) was significant and its relationship with patient’s survival was insignificant statistically. However, there was a clear difference as mean survival age of patients based on CD24 expression was 26.64±18.15 for negative cases and 41.75±28.76 months for positive cases. CD24 and CD133 expressions and their co-expression with other clinic-pathological factors were not significant. CONCLUSION: During this study, the relationship between CD24 and treatment type was significant. To confirm this result, various studies with high sample numbers and other stem cell markers are recommended.
format Online
Article
Text
id pubmed-4833852
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-48338522016-04-20 Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran Nosrati, Anahita Naghshvar, Farshad Maleki, Iradj Salehi, Fatemeh Gastroenterol Hepatol Bed Bench Brief Report AIM: We aimed to study the expression of CD24 and CD133 in colorectal cancer and normal adjacent tissues to assess a relationship between these markers and clinic-pathological characteristics and patient’s survival. BACKGROUND: Cancer stem cells are a group of tumor cells that have regeneration and multi-order differentiation capabilities. PATIENTS AND METHODS: Expression of CD24 and CD133 was studied in a paraffin block of colorectal cancer and normal tissues near tumors with the immuneohistochemical method in patients who were referred to Imam Khomeini Hospital in Sari. RESULTS: A total of 50 samples (25 males and 25 females) with a mean age of 67.57±13.9 years old with range 28-93 years, included 3 mucinous carcinoma and 47 adenocarcinoma. Expression of CD133 marker was negative in 29 cases and positive in 21 cases. Expression of CD24 in tissue near tumor cells was found in 30% of available samples. The relationship between expressing CD24 with treatment (surgery and chemotherapy) was significant and its relationship with patient’s survival was insignificant statistically. However, there was a clear difference as mean survival age of patients based on CD24 expression was 26.64±18.15 for negative cases and 41.75±28.76 months for positive cases. CD24 and CD133 expressions and their co-expression with other clinic-pathological factors were not significant. CONCLUSION: During this study, the relationship between CD24 and treatment type was significant. To confirm this result, various studies with high sample numbers and other stem cell markers are recommended. Shaheed Beheshti University of Medical Sciences 2016 /pmc/articles/PMC4833852/ /pubmed/27099673 Text en ©2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Nosrati, Anahita
Naghshvar, Farshad
Maleki, Iradj
Salehi, Fatemeh
Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title_full Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title_fullStr Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title_full_unstemmed Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title_short Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
title_sort cancer stem cells cd133 and cd24 in colorectal cancers in northern iran
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833852/
https://www.ncbi.nlm.nih.gov/pubmed/27099673
work_keys_str_mv AT nosratianahita cancerstemcellscd133andcd24incolorectalcancersinnortherniran
AT naghshvarfarshad cancerstemcellscd133andcd24incolorectalcancersinnortherniran
AT malekiiradj cancerstemcellscd133andcd24incolorectalcancersinnortherniran
AT salehifatemeh cancerstemcellscd133andcd24incolorectalcancersinnortherniran